Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors

Jacopo Chiaro, Gabriella Antignani, Sara Feola, Michaela Feodoroff, Beatriz Martins, Hanne Cojoc, Salvatore Russo, Manlio Fusciello, Firas Hamdan, Valentina Ferrari, Daniele Ciampi, Ilkka Ilonen, Jari Räsänen, Mikko Mäyränpää, Jukka Partanen, Satu Koskela, Jarno Honkanen, Jussi Halonen, Lukasz Kuryk, Maria RescignoMikaela Grönholm, Rui M. Branca, Janne Lehtiö, Vincenzo Cerullo

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Abstrakti

Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. As the available therapeutic options show a lack of efficacy, novel therapeutic strategies are urgently needed. Given its T-cell infiltration, we hypothesized that MPM is a suitable target for therapeutic cancer vaccination. To date, research on mesothelioma has focused on the identification of molecular signatures to better classify and characterize the disease, and little is known about therapeutic targets that engage cytotoxic (CD8+) T cells. In this study we investigate the immunopeptidomic antigen-presented landscape of MPM in both murine (AB12 cell line) and human cell lines (H28, MSTO-211H, H2452, and JL1), as well as in patients’ primary tumors. Applying state-of-the-art immuno-affinity purification methodologies, we identify MHC I-restricted peptides presented on the surface of malignant cells. We characterize in vitro the immunogenicity profile of the eluted peptides using T cells from human healthy donors and cancer patients. Furthermore, we use the most promising peptides to formulate an oncolytic virus-based precision immunotherapy (PeptiCRAd) and test its efficacy in a mouse model of mesothelioma in female mice. Overall, we demonstrate that the use of immunopeptidomic analysis in combination with oncolytic immunotherapy represents a feasible and effective strategy to tackle untreatable tumors.

Alkuperäiskielienglanti
Artikkeli7056
LehtiNature Communications
Vuosikerta14
Numero1
Sivumäärä16
ISSN2041-1723
DOI - pysyväislinkit
TilaJulkaistu - jouluk. 2023
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Lisätietoja

Publisher Copyright:
© 2023, The Author(s).

Tieteenalat

  • 3111 Biolääketieteet
  • 3122 Syöpätaudit

Siteeraa tätä